Article Text

Download PDFPDF
Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?

Statistics from


  • Competing interests Professor Tak has served as a consultant to Genentech and Roche.

  • Patient consent Obtained.

  • Ethics approval Medical Ethical Committee of Academic Medical Center/University of Amsterdam.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.